RxDoctor Payments Data

Paramarajan Piranavan, MD

Rheumatology · Lexington, KYNPI 1295186799

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $6,371 of the $8,316 with a category attached, or 76.6%. 6 manufacturers reported payments, led by AstraZeneca at 47.0% of the total. 2025 is the largest year on record at $5,329, more than ten times the $160 reported in 2019.

$8,316in general payments, 2019–2025

Across 23 payments — averaging $361.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$4K
  • Amgen$3K
  • Novartis$2K
  • Cardinal Health 110 LLC$100
  • Genentech USA, Inc.$100
  • Biogen$41
$275,090in research payments, 2019–2025

Across 7 payments — averaging $39,299 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Amgen$248K
  • Novartis$27K

What the payments were for

  • Consulting fees$6,37177%
  • Travel & lodging$94511%
  • Food & beverage$89211%
  • Education$1081%

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca8$3,906
Amgen3$2,559
Novartis8$1,610
Cardinal Health 110 LLC1$100
Genentech USA, Inc.1$100
Biogen2$41

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,316 in reported general payments places this provider in the 70th percentile of 81 rheumatology providers in Kentucky.

See all rheumatology providers in Kentucky

Medicare billing

Part B allowed, 2024
$31,263
Medicare patients
139
Services billed
319

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab112$1,092,092
RinvoqUpadacitinib85$525,063
Humira PenAdalimumab64$411,633
Enbrel SureclickEtanercept47$351,723
Cosentyx Sensoready (2 Pens)Secukinumab40$299,465
Humira(Cf)Adalimumab36$269,981
Orencia ClickjectAbatacept45$242,284
HumiraAdalimumab25$237,547
Bimzelx AutoinjectorBimekizumab-Bkzx12$176,868
Actemra ActpenTocilizumab45$145,754
Gamunex-CImmune Globul G/Gly/Iga Avg 4612$107,994
Taltz AutoinjectorIxekizumab11$100,207
OtezlaApremilast20$95,907
Enbrel MiniEtanercept13$85,886
EnbrelEtanercept11$80,673

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla, Enbrel$2,559$176,58031 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 81 rheumatology providers in Kentucky.

Other rheumatology in Lexington

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →